Sympathomimetic decongestants during pregnancy: risks for the unborn child.

Prescrire international 2016 Jun

filter terms:

all
compound
phenotype
tissue
show more »
show less «

In addition to the risk of cardiovascular events and neurological disorders, sympathomimetic decongestants have teratogenic potential, albeit weak, when taken during the first trimester of pregnancy, probably through disruption of the vascular system of the embryo and the pregnant woman. In the second and third trimesters of pregnancy, the fetus is exposed to the same adverse effects as the mother.